Clinical Trial

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Study acronym: TRANSCAPE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-10-10; most recent amendment 2026-06-04.
Trial Details
NCT Number NCT06084780
Lead Sponsor Case Comprehensive Cancer Center
Conditions Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
Enrollment 20 participants
Start Date 2026-08
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10